[en] Objective: The most widely studied positron emission tomography ligand for in vivo -amyloid imaging is 11CPittsburgh compound B (11C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the 18F-labeled PIB derivative 18F-flutemetamol could significantly enhance access to this novel technology.
Methods: Twenty-seven patients with early-stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15 cognitively intact healthy volunteers (HVs) above and 10 HVs below 55 years of age participated. The primary endpoint was the efficacy of blinded visual assessments of 18F-flutemetamol scans in assigning subjects to a raised versus normal uptake category, with clinical diagnosis as the standard of truth
(SOT). As secondary objectives, we determined the correlation between the regional standardized uptake value ratios (SUVRs) for 18F-flutemetamol and its parent molecule 11C-PIB in 20 of the AD subjects and 20 of the MCI patients. We also determined test-retest variability of 18F-flutemetamol SUVRs in 5 of the AD subjects.
Results: Blinded visual assessments of 18F-flutemetamol scans assigned 25 of 27 scans from AD subjects and 1 of 15 scans from the elderly HVs to the raised category, corresponding to a sensitivity of 93.1% and a specificity of 93.3% against the SOT. Correlation coefficients between cortical 18F-flutemetamol SUVRs and 11C-PIB SUVRs ranged from 0.89 to 0.92. Test-retest variabilities of regional SUVRs were 1 to 4%.
Interpretation: 18F-Flutemetamol performs similarly to the 11C-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use.
Research center :
GIGA CRC (Cyclotron Research Center) In vivo Imaging-Aging & Memory - ULiège
Disciplines :
Neurology
Author, co-author :
Vandenberghe, R.
Van Laere, K.
Ivanoiu, A.
Salmon, Eric ; Université de Liège - ULiège > Département des sciences cliniques > Neuroimagerie des troubles de la mémoire et révalid. cogn.
Bastin, Christine ; Université de Liège - ULiège > Centre de recherches du cyclotron
Triau, E.
Hasselbalch, S.
Law, I.
Andersen
Korner, A.
Minthon, L.
Garraux, Gaëtan ; Université de Liège - ULiège > Département des sciences cliniques > Neurologie
Klunk W, Wang Y, Huang C, et al. The binding of 2-(4′ methyl-aminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-2092. (Pubitemid 36368896)
Klunk W, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319. (Pubitemid 38269583)
Lockhart A, Lamb J, Osredkar T, et al. PIB is a non-specific imaging marker of Aβ peptide-related cerebral amyloidosis. Brain 2007;130:2607-2615. (Pubitemid 47511709)
Ikonomovic M, Klunk W, Abrahamson E, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-1645. (Pubitemid 351806448)
Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with 11C-labeled Pittsburgh compound B. Arch Neurol 2008;65:1304-1309.
Fodero-Tavoletti M, Smith D, McLean C, et al. In vitro characteristics of Pittsburgh compound B binding to Lewy bodies. J Neurosci 2007;26:10365-10371.
Nelissen N, Vandenbulcke M, Fannes K, et al. Aβ amyloid deposition in the language system and how the brain responds. Brain 2007;130:2055-2069. (Pubitemid 47236621)
Rowe C, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology 2007;68:1718-1725. (Pubitemid 46763260)
Johnson K, Gregas M, Becker J, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234. (Pubitemid 47525398)
Rabinovici G, Jagust W, Furst A, et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008;64:388-401.
Edison P, Rowe C, Rinne J, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
Wolk D, Price J, Saxton J, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557-568.
Pike K, Savage G, Villemagne VL, et al. β Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-2844.
Reiman E, Chen K, Liu X, et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:6820-6825.
Morris J, Roe C, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67;122-131.
Verhoeff N, Wilson A, Takeshita S, et al. In vivo imaging of Alzheimer disease β amyloid with 11C-SB-13. Am J Geriatr Psychiatry 2004;12:584-595.
Small G, Kepe V, Ercoli L, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-2663. (Pubitemid 44969124)
Tolboom N, Yaqub M, van der Flier W, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009;50:191-197.
Rowe C, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:114-115.
Koole M, Lewis D, Buckley C, et al. Whole-body distribution and radiation dosimetry of 18F-GEO67: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50:818-822.
Nelissen N, Van Laere K, Thurfjell L, et al. Phase I study of the PIB derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer's disease. J Nucl Med 2009;50:1251-1259.
Petersen R, Smith G, Waring S, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308. (Pubitemid 29120227)
Scheinin N, Tolvanen T, Wilson I, et al. Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med 2007;48:128-133.
McNamee R, Yee S, Price J, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009;50:348-355.
Andersson J, Thurfjell L. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assist Tomogr 1997;21:136-144. (Pubitemid 27061172)
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in spm using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289. (Pubitemid 34852226)
Lopresti B, Klunk W, Mathis C, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 2005;46:1959-1972. (Pubitemid 46657441)
Chui H, Lee A. Clinical criteria for dementia subtypes. In: Qizilbash N, Schneider L, Chui H, et al, eds. Evidence-based dementia practice. Oxford, UK: Blackwell, 2003:106-119.
Driscoll I, Resnick S, Troncoso J, et al. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol 2006;60:688-695. (Pubitemid 46048486)
Fodero-Tavoletti M, Rowe C, McLean C, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med 2009;50:198-204.
Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Aβ42 immunisation in Alzheimers disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-223. (Pubitemid 351978111)
Rinne J, Brooks D, Rossor M, et al. 11C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzimab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.
